Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for Tremfya
December 03, 2024
December 03, 2024
NEW BRUNSWICK, New Jersey, Dec. 3 -- Johnson and Johnson issued the following news release:
* * *
Applications filed for TREMFYA to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis
* * *
SPRING HOUSE, Pa. (December 2, 2024) - Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval . . .
* * *
Applications filed for TREMFYA to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis
* * *
SPRING HOUSE, Pa. (December 2, 2024) - Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval . . .